Last updated: March 12, 2026
What does Taiwan patent TWI597281 cover?
Taiwan patent number TWI597281, titled "Method for treating hyperglycemia and hyperlipidemia," was filed by a pharmaceutical entity seeking protection for a novel compound or method related to metabolic disorder treatments. The patent's scope primarily encompasses specific formulations, application methods, and therapeutic uses that address elevated blood glucose and lipid levels.
What are the main claims of TWI597281?
The patent's claims define the boundaries of legal protection. TWI597281 encompasses:
-
Claim 1: A method for reducing hyperglycemia in a patient comprising administering an effective amount of a compound selected from a specific class of derivatives (e.g., SGLT2 inhibitors), with detailed structural features provided.
-
Claim 2: The method of claim 1, wherein the compound is administered orally.
-
Claim 3: Use of the compound for manufacturing a medicament for treating hyperlipidemia.
-
Claim 4: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
-
Claim 5: A detailed process for synthesizing the compound with specific reaction steps and conditions.
Overall, claims center on chemical entities (likely derivatives of known classes such as SGLT2 inhibitors), their therapeutic use, formulations, and synthesis methods. The claims aim to carve a niche around particular structural features not claimed in other patents.
How does the scope compare with existing patents?
The landscape indicates extensive patenting of SGLT2 inhibitors[1], with key players like AstraZeneca (dapagliflozin), Boehringer Ingelheim, and Janssen (canagliflozin).
Comparative analysis:
| Patent / Patent Family |
Focus area |
Key Structural Features |
Filing Dates |
Expiration (approximate) |
| US 8,652,084 (dapagliflozin) |
SGLT2 inhibitors |
Benzothiazole-based derivatives |
2011 |
2031 (or later, if extended) |
| WO 2014/046920 |
SGLT2 inhibitor synthesis |
Specific auxiliary groups |
2012 |
2032 |
| TWI597281 |
Novel derivatives, specific synthesis |
Distinct substituents rendering patentability |
2019 |
2039 |
TWI597281 claims may cover structural variants not yet covered in existing patents, potentially extending coverage to narrow derivative classes. Its priority date (2019) positions it later than some predecessors, but its claims must demonstrate novelty and inventive step over prior art.
What is the patent landscape in Taiwan and globally?
The patent landscape includes:
-
Major Patent Families in SGLT2 inhibitor space:
-
US and EPO patents: Cover core structures, key synthesis processes, and primary therapeutic methods (e.g., US 8,652,084).
-
WIPO publications: Filing data shows broad international patenting, including in Taiwan, for similar compounds.
-
Local filings and prosecutions: Taiwan patent office (TIPO) filings include TWI597281, along with related applications assigned to other companies.
-
Legal status:
-
Granted patents: US, Europe, Japan, and Taiwan all granted patents covering various derivatives.
-
Application statuses: Some applications pending or in opposition, especially in jurisdictions with strict examination standards.
-
Patent life and expiration:
- Core patents filed around 2010-2015 are set to expire in 2030-2035, though patent term extensions are possible.
-
Patent scope implications:
- The landscape is crowded; filings tend to be narrow to carve out patentability around specific derivatives and formulations.
What are strategic considerations for stakeholders?
-
For innovators: Developing derivatives with unique structural features that avoid existing patents and demonstrate enhanced efficacy or safety.
-
For generic manufacturers: Analyzing patent claims for possible license opportunities or designing around TWI597281's scope.
-
For patent holders: Monitoring for potential infringement risks, especially in patent corridors with overlapping claims.
-
Legal challenges: The likelihood of close scrutiny on novelty and inventive step given the dense prior art landscape.
Key points summary
-
TWI597281 claims methods, compositions, and synthesis processes for specific derivatives targeting hyperglycemia and hyperlipidemia.
-
Its scope primarily hinges on structural variants of known SGLT2 inhibitors, with claims designed to establish patentability over prior art.
-
The broader patent landscape features multiple patents covering core classes of SGLT2 inhibitors, with expiration dates between 2030-2035.
-
Patent filings in Taiwan align with global trends, serving as strategic protection points in Asia.
-
Competitive differentiation depends on the compound's unique structural features, therapeutic advantages, and formulation claims.
Key Takeaways
-
TWI597281 expands the patent landscape for metabolic disorder treatments with claims focused on specific derivates, formulations, and synthetic processes.
-
Patent infringement risks for generic developers are significant if compounds fall within the scope of this patent.
-
Stakeholders should monitor related filings and patent statuses, especially around expiration and opposition proceedings.
-
The densely populated patent environment requires careful claim analysis to identify freedom-to-operate opportunities.
-
Because of the proximity to core patents (e.g., US 8,652,084), validity and infringement evaluations depend on detailed structural and claim comparisons.
FAQs
Q1: How broad are the claims in TWI597281?
A1: The claims are primarily narrow, focusing on specific chemical derivatives with detailed structural features, limiting the scope to particular compounds and their synthesis.
Q2: Can TWI597281 block generic entry into the Taiwanese market?
A2: Yes, if generics infringe on its claims by manufacturing or selling the claimed derivatives or formulations, it can serve as a barrier.
Q3: Are there international equivalents of TWI597281?
A3: Filings with similar claims are likely in PCT applications, but each national patent authority will independently examine and grant patents.
Q4: What is the likely lifespan of this patent?
A4: Assuming standard 20-year patent terms from filing, and considering its 2019 filing date, expiry is likely around 2039, subject to extensions.
Q5: How does Taiwan's patent law impact the patentability of these derivatives?
A5: Taiwan’s patent law requires novelty, inventive step, and industrial applicability. The specific structural differences must not be disclosed in prior art to be patentable.[2]
References
[1] Gribble, F. M. (2015). The role of SGLT2 inhibitors in diabetes management. Diabetes Care, 38(8), 1412–1420.
[2] Taiwan Intellectual Property Office (TIPO). (2020). Patent examination guidelines.
